Benzoic Acid

Benzoic Acid

SCHEMBL177939

O=C(O)c1ccccc1.[Cl-].[Na+]

nearest known ligand 0.88

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D

The experimentally established mechanism targets of Benzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.88
NAPRT Q6XQN6 2/20 0.88
DAO P14920 1/20 0.88
CES2 O00748 3/20 0.70
CES1 P23141 3/20 0.70
SRD5A2 P31213 2/20 0.70
TP53 P04637 1/20 0.65
ALDH1A1 P00352 2/20 0.58
CA2 P00918 3/20 0.57
CA4 P22748 3/20 0.57
APP P05067 1/20 0.54
GAA P10253 1/20 0.54
HCAR3 P49019 1/20 0.54
HCAR2 Q8TDS4 1/20 0.54
TRPA1 O75762 1/20 0.54
CA12 O43570 2/20 0.52
CA1 P00915 2/20 0.52
CA3 P07451 2/20 0.52
CA6 P23280 2/20 0.52
CA5A P35218 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzoic Acid SCHEMBL9628835 0.97 TSHR (0.93) TSHRNAPRTDAOCES2CES1
Benzoic Acid SCHEMBL9115470 0.97 TSHR (0.93) TSHRNAPRTDAOCES2CES1
Benzoic Acid SCHEMBL19326692 0.94 TSHR (0.88) TSHRNAPRTDAOCES2CES1
Benzoic Acid SCHEMBL11599602 0.94 TSHR (0.88) TSHRNAPRTDAOCES2CES1
Benzoic Acid SCHEMBL4905361 0.94 TSHR (0.88) TSHRNAPRTDAOCES2CES1
Benzoic Acid SCHEMBL8392389 0.94 TSHR (0.88) TSHRNAPRTDAOCES2CES1
Benzoic Acid SCHEMBL29101150 0.94 TSHR (0.88) TSHRNAPRTDAOCES2CES1
Benzoic Acid SCHEMBL30413123 0.94 TSHR (0.88) TSHRNAPRTDAOCES2CES1
Benzoic Acid SCHEMBL3966600 0.94 TSHR (1.00) TSHRNAPRTDAOCES2CES1
Benzoic Acid SCHEMBL976149 0.94 TSHR (1.00) TSHRNAPRTDAOCES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2698145-B1 Pharmaceutical Formulations comprising dapoxetine and a PDE5 inhibitor MONTERO GIDA SANAYI VE TICARET AS (TR) 2020-12-02 EP claimed
US-20160008375-A1 PHARMACEUTICAL FORMULATIONS COMPRISING QUETIAPINE AND ESCITALOPRAM SANOVEL ILAC SANAYI VE TICARET A.S. (TR) 2016-01-14 US claimed
EP-2961390-A1 PHARMACEUTICAL FORMULATIONS COMPRISING QUETIAPINE AND ESCITALOPRAM Sanovel Ilac Sanayi ve Ticaret A.S. (TR) 2016-01-06 EP claimed
EP-2956125-A1 ORAL PHARMACEUTICAL FORMULATIONS COMPRISING NIMESULIDE AND THIOCOLCHICOSIDE Sanovel Ilac Sanayi ve Ticaret A.S. (TR) 2015-12-23 EP claimed
EP-2793853-B1 PHARMACEUTICAL FORMULATIONS OF FLURBIPROFEN AND GLUCOSAMIN SANOVEL ILAC SANAYI VE TICARET (TR) 2015-12-16 EP claimed
US-20150216798-A1 NOVEL ORALLY ADMINISTERED PHARMACEUTICAL FORMULATIONS SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) 2015-08-06 US claimed
US-20150196506-A1 CHEWING GUM FORMULATIONS COMPRISING DAPOXETINE AND TADALAFIL Sanovel llac Sanayi Ve Ticaret Anonim Sirketi (TR) 2015-07-16 US claimed
US-20150010627-A1 NEW PHARMACEUTICAL COMPOSITIONS OF FLURBIPROFEN AND GLUCOSAMIN SANOVEL ILAC SANAYI VE TICARET (TR) 2015-01-08 US claimed
US-20140363508-A1 PHARMACEUTICAL FORMULATIONS OF FLURBIPROFEN AND GLUCOSAMIN SANOVEL SANAYI VE TICARET ANONIM SIRKETI (TR) 2014-12-11 US claimed
EP-2809306-A2 NEW PHARMACEUTICAL COMPOSITIONS OF FLURBIPROFEN AND GLUCOSAMIN Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) 2014-12-10 EP claimed
WO-2013095317-A2 PHARMACEUTICAL FORMULATIONS OF FLURBIPROFEN AND GLUCOSAMIN SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) 2013-06-27 WO claimed
EP-2394638-B1 New pharmaceutical combinations SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) 2013-05-08 EP claimed
EP-2547330-A2 ORALLY DISINTEGRATING TABLET FORMULATIONS OF DONEPEZIL AND PROCESS FOR PREPARING THE SAME Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi (TR) 2013-01-23 EP claimed
EP-2468361-A1 Vildagliptin Formulations Sanovel Ilac Sanayi ve Ticaret A.S. (TR) 2012-06-27 EP claimed
EP-2407159-A1 Pharmaceutical compositions of olmesartan Sanovel Ilac Sanayi ve Ticaret A.S. (TR) 2012-01-18 EP claimed
US-20110305757-A1 NEW PHARMACEUTICAL COMBINATIONS SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) 2011-12-15 US claimed
EP-2394638-A1 New Pharmaceutical Combinations Sanovel Ilac Sanayi ve Ticaret A.S. (TR) 2011-12-14 EP claimed
EP-2295040-B1 Pharmaceutical compositions of pramipexole SANOVEL ILAC SANAYI VE TICARET AS (TR) 2011-10-12 EP claimed
WO-2011115599-A2 ORALLY DISINTEGRATING TABLET FORMULATIONS OF DONEPEZIL AND PROCESS FOR PREPARING THE SAME SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) 2011-09-22 WO claimed
EP-2295040-A1 Pharmaceutical compositions of pramipexole Sanovel Ilac Sanayi ve Ticaret A.S. (TR) 2011-03-16 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150010627-A1 NEW PHARMACEUTICAL COMPOSITIONS OF FLURBIPROFEN AND GLUCOSAMIN SLC5A1, SLC35B2, SLC5A2 TSHR 2769/4885NAPRT 76/4885DAO 1731/4885
US-20160008375-A1 PHARMACEUTICAL FORMULATIONS COMPRISING QUETIAPINE AND ESCITALOPRAM SLC6A4, SLC6A2, SLC6A3 TSHR 2655/4885NAPRT 1930/4885DAO 3963/4885
US-20110305757-A1 NEW PHARMACEUTICAL COMBINATIONS REN, SLC5A1, SLC5A2 TSHR 886/4885NAPRT 2557/4885DAO 4170/4885
US-20150196506-A1 CHEWING GUM FORMULATIONS COMPRISING DAPOXETINE AND TADALAFIL PDE5A, PDE3A, PDE3B TSHR 4234/4885NAPRT 114/4885DAO 287/4885
US-20140363508-A1 PHARMACEUTICAL FORMULATIONS OF FLURBIPROFEN AND GLUCOSAMIN SLC5A1, SLC2A3, SLC2A1 TSHR 1532/4885NAPRT 42/4885DAO 2118/4885
US-20150216798-A1 NOVEL ORALLY ADMINISTERED PHARMACEUTICAL FORMULATIONS PDE5A, PDE12, PDE3A TSHR 4459/4885NAPRT 571/4885DAO 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.